Physician profile
David Danly
NPI 1376519272
$5,477.06
in general payments reported to CMS, 2019-2025
18 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $363 · 2021: $659 · 2022: $514 · 2023: $726 · 2024: $1,249 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,465 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.93 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $861.49 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $796.09 | 2020-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $725.83 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $713.49 | 2020-2025 | Uzedy, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $670.36 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $401.02 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $311.37 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $288.41 | 2024-2025 | Cobenfy |
| Indivior INC. | $267.26 | 2023-2024 | Perseris |
| Lundbeck LLC | $115.60 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $80.05 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $56.91 | 2019-2025 | Invega Sustenna |
| Corium, LLC | $51.97 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $44.50 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $38.17 | 2019-2024 | Trintellix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.50 | 2020 | |
| Eisai INC. | $17.31 | 2021 | |
| Noven Therapeutics, LLC | $13.73 | 2025 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Danly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.